Immix Biopharma (IMMX) Expected to Announce Quarterly Earnings on Thursday

Immix Biopharma (NASDAQ:IMMX) is expected to post its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect Immix Biopharma to post earnings of ($0.1450) per share for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.12). On average, analysts expect Immix Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immix Biopharma Stock Up 7.9%

IMMX stock opened at $10.32 on Thursday. Immix Biopharma has a 52 week low of $1.87 and a 52 week high of $11.61. The firm has a market capitalization of $547.08 million, a P/E ratio of -11.60 and a beta of 0.12. The company has a fifty day simple moving average of $9.32 and a two-hundred day simple moving average of $6.60.

Wall Street Analyst Weigh In

A number of brokerages recently commented on IMMX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Tuesday, April 21st. Mizuho boosted their price objective on Immix Biopharma from $14.00 to $15.00 and gave the stock an “outperform” rating in a research note on Monday, March 30th. Morgan Stanley started coverage on Immix Biopharma in a research note on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 price objective for the company. Citizens Jmp reiterated a “market outperform” rating and issued a $23.00 target price on shares of Immix Biopharma in a report on Friday, March 27th. Finally, HC Wainwright boosted their target price on Immix Biopharma from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.25.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC purchased a new stake in shares of Immix Biopharma in the 4th quarter worth approximately $20,471,000. Marshall Wace LLP raised its position in shares of Immix Biopharma by 3,495.4% in the 4th quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock worth $10,349,000 after acquiring an additional 1,923,708 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Immix Biopharma during the 4th quarter worth $8,681,000. Adage Capital Partners GP L.L.C. purchased a new position in Immix Biopharma in the fourth quarter valued at about $7,845,000. Finally, Logos Global Management LP bought a new position in Immix Biopharma in the fourth quarter worth about $5,230,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.